New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
08:02 EDTCVMCEL-SCI receives $225K NIH research grant
CEL-SCI announced that it has been awarded a Phase I Small Business Innovation Research grant in the amount of $225K from the National Institute of Arthritis Muscoskeletal and Skin Diseases, which is part of the National Institutes of Health. The grant will fund the further development of CEL-SCI’s LEAPS technology as a potential treatment for rheumatoid arthritis. The NIH grant was awarded based on preliminary data by Tibor Glant’s team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental RA when it was administered after the disease was induced in the animals. This data was presented in May 2013 by Daniel Zimmerman, CEL-SCI’s senior vice president of research, cellular immunology, at the symposium on “Therapeutic Approaches to Autoimmunity” during the American Association of Immunologists 100th annual meeting in Honolulu, Hawaii.
News For CVM From The Last 14 Days
Check below for free stories on CVM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
08:42 EDTCVMFrance clears CEL-SCI for patient enrollment in Phase III trial
CEL-SCI announced that the French Agency for the Safety of Health Products has cleared the company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in France. In the past three months CEL-SCI has also received governmental clearance to expand its trial into the United Kingdom, Austria, Sri Lanka and Turkey. CEL-SCI’s Phase III trial is assessing the company’s investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.
July 23, 2014
08:11 EDTCVMCEL-SCI cleared to begin patient enrollment
Subscribe for More Information
July 22, 2014
08:32 EDTCVMCEL-SCI receives clearance to expand Multikine Phase III trial to Turkey
Subscribe for More Information
July 17, 2014
08:45 EDTCVMCEL-SCI expands Phase III head and neck cancer trial into Sri Lanka
CEL-SCI announced that Sri Lanka’s Ministry of Health has cleared the company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in Sri Lanka. This follows similar clearance to conduct the Phase III study in the UK and Austria during the past weeks. Further expansion of the trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers in 20 countries by the end of 2015. The trial, which already has over 220 patients enrolled, is assessing the company’s investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use